107 results about "Human melanoma" patented technology

Attenuated recombinant viruses containing DNA coding for a cytokine and / or a tumor associated antigen, as well as methods and compositions employing the viruses, are disclosed and claimed. The recombinant viruses can be NYVAC or ALVAC recombinant viruses. The DNA can code for at least on of: human tumor necrosis factor; nuclear phosphoprotein p53, wildtype or mutant; human melanoma-associated antigen; IL-2; IFNgamma; IL-4; GNCSF; IL-12; B7; erb-B-2 and carcinoembryonic antigen. The recombinant viruses and gene products therefrom are useful for cancer therapy.

Attenutated recombinant viruses containing DNA coding for a cytokine and / or a tumor associated antigen, as well as methods and compositions employing the viruses, are disclosed and claimed. The recombinant viruses can be NYVAC or ALVAC recombinant viruses. The DNA can code for at least one of: human tumor necrosis factor; nuclear phosphoprotein p53, wiltype or mutant; human melanoma-associated antigen; IL-2; IFNgamma; IL-4; GMCSF; IL-12; B7; erb-B-2 and carcinoembryonic antigen. The recombinant viruses and gene products therefrom are useful for cancer therapy.

The invention provides melanoma cell specific adenovirus vectors, which preferentially replicate in melanoma cells.

The invention belongs to the technical field of molecular biology and biomedicine and in particular relates to application of a gRNA (guide Ribonucleic Acid) sequence based on a CRISPR / Cas9 (Clustered Regularly Interspaced Short Palindromic Repeats / CRISPR associated protein 9) system on knockout of a human Lin28A gene and application to tumor treatment. According to a design principle of CRISPR / Cas9, 6 guide RNAs (gRNA) are designed and a sequence table is shown as SEQ ID NO.1 to SEQ ID NO.6; the guide RNAs are constructed on a PX458 carrier and two efficient target gRNAs are obtained through activity detection and screening. The CRISPR / Cas9 system guided by the two gRNAs is utilized in human hepatocellular carcinoma cell lines (HepG2) and human melanoma cell lines (A375), and the human Lin28A gene can be effectively knocked out; the system is easy to operate and the human Lin28A gene knockout efficiency is high, so that the system is applicable to various tumor cell models. The gRNA provided by the invention is hopefully applied to a new drug for treating tumors.

Autotaxin (ATX) is a prometastatic enzyme initially isolated from the conditioned media of human melanoma cells that stimulates a myriad of biological activities including angiogenesis and the promotion of cell growth, survival, and differentiation through the production of lysophosphatidic acid (LPA). ATX increases the aggressiveness and invasiveness of transformed cells, and ATX levels directly correlate with tumor stage and grade in several human malignancies. To study the role of ATX in the pathogenesis of malignant melanoma, we developed antibodies and small molecule inhibitors against recombinant human protein. Immunohistochemistry of paraffin embedded human tissue demonstrates that ATX levels are markedly increased in human primary and metastatic melanoma relative to benign nevi. Chemical screens identified several small molecule inhibitors with binding constants ranging from nanomolar to low micromolar. Cell migration and invasion assays with melanoma cell lines demonstrate that ATX markedly stimulates melanoma cell migration and invasion, an effect suppressed by ATX inhibitors. The migratory phenotype can be rescued by the addition of ATX's enzymatic product, LPA, confirming that the observed inhibition is linked to suppression of LPA production by ATX. Chemical analogues of the inhibitors demonstrate structure activity relationships important for ATX inhibition and indicate pathways for their optimization. These studies suggest that ATX is an approachable molecular target for the rational design of chemotherapeutic agents directed against human malignancies driven by the ATX / LPA axis, especially including malignant melanoma, among numerous others including breast and ovarian cancers.

The invention provides a long non-coding RNA (long non-coding RNA, 1ncRNA)-incRNA-HN3 sequence relevant to human melanoma cells, and an RNA interference (RNA interference, RNAi) target spot sequence, a short-hairpin RNA (short-hairpin RNA, shRNA) sequence, an shRNA coded small molecule interference RNA (small interference RNA, siRNA), a coding shRNA coding strand and an anti-sense strand DNA sequence, coding shRNA recombinant plasmids of the long non-coding RNA sequence, and the invention relates to the applications of the long non-coding RNA sequence for preparing reagents for diagnosing melanoma diseases and drugs for treating the melanoma diseases.

The invention discloses a long non-coding RNA (lnc RNA-UN) of human melanoma cell specific expression, an RNA interfering target spot thereof, a short hairpin RNA (shRNA) of the RNA interfering target spot, a small interfering RNA (siRNA), a sense strand DNA and an antisense strand DNA of the coding short hairpin RNA and a recombinant plasmid of a transcription short hairpin RNA. Proved by experiments, the lnc RNA-UN is highly expressed in a melanoma tissue and not expressed in a peficancerous tissue and can be applied to preparing a reagent for diagnosing melanoma diseases. Proved by the experiments, the recombinant plasmid of the transcription short hairpin RNA expresses the shRNA and the siRNA in a melanoma cell and can obviously degrade the cell endogenous lncRNA-UN and restrain the malignant growth of the melanoma cell, thus the shRNA and the siRNA of the RNA interfering target spot of the lncRNA-UN and the recombinant plasmid of the transcription short hairpin RNA can be applied to medicaments for treating the melanoma diseases.

A method of treating melanoma or a metastasis thereof in a human patient by administering a melanoma-treating effective amount of an alpha thymosin peptide to a human melanoma patient, wherein the human melanoma patient does not have a substantially elevated LDH blood level.

Melanoma or a metastasis thereof is treated in a human patient in a combination therapy which includes administering a melanoma-treating combination to a human melanoma patient during a treatment regimen, the combination including an alpha thymosin peptide and antibodies against cytotoxic T lymphocyte-associated antigen 4 (CTLA4).

The invention discloses a highly metastatic model of human melanoma, a highly metastatic cell subline of the human melanoma, creation methods for the highly metastatic model and the highly metastatic cell subline, and the dynamic detection of metastasis. The subcutaneously-transplanted mouse highly metastatic model and the corresponding cell subline are established in an in-vivo screening way in a mouse with severe combined immune deficiency (SCID) by using mouse lung metastasis, namely human malignant melanoma cell strain A375 pulmonary metastasis, wherein the highly metastatic cell subline of the human melanoma is A375sci, and has a human tumor cell karyotype; and 60 to 75 hypo-triploid-dominated chromosomes are acrocentric and have a heteroploid karyotype. The cell subline has the two routes of metastasis of blood trails and lymph. The in-vivo screening of the highly-metastatic model is performed by using animals with severe immune deficiency, and is expressed and applied in nude mice. A method for detecting Alu genes by using a polymerase chain reaction (PCR) method is simple, highly sensitive and highly specific, and can be used for detecting organ metastasis, particularly micrometastasis, in a human tumor animal-xenotransplantation model.

Cyclic peptide compounds and derivatives thereof having antitumor activity as shown by treatment of human melanoma, pancreatic, breast, prostate cancer cells.

The invention relates to a targeted anti-malignant-melanoma DTIC (dacarbazine) and miR-205 co-carrying exosome as well as a preparation method and application thereof. The condition that DTIC and miR-205 achieve a cooperated inhibition effect on the human melanoma through being used in a combined way is discovered; a cholesterol modified DNA aptamer Ap16 is used as a targeted head; exosomes from the middle lactation period of milk are coated and carried with DTIC and miR-205; an Ap16-exosome / (DTIC / miR-205) nanometer medication system is successfully built by a freeze thawing method; the cooperated anti-tumor effect of the DTIC and miR-205 is proved; the aptamer Ap16 mediated co-carrying exosomes improve the feasibility of the miR-205 for enhancing the anti-malignant-melanoma effect of the DTIC. The invention provides a novel path for building the anti-malignant-melanoma nanometer medication system, and also provides the theoretical basis for the combined use of gene therapy and chemotherapy.

Melanoma or a metastasis thereof is treated in a human patient in a combination therapy which includes administering a melanoma-treating combination to a human melanoma patient during a treatment regimen, the combination including an alpha thymosin peptide and an antineoplastic heat shock apoptosis activator (HSAA) such as STA-4783 (and optionally an antineoplastic cytotoxic chemotherapeutic agent such as paclitaxel), and / or optionally one or more additional anti-melanoma agents.

The present invention relates to the field of melanoma diagnosis and therapy. In particular, the present invention relates to c-kit activating mutations present in melanoma, and their use for melanoma evaluation and diagnosis, melanoma prognosis, melanoma progression monitoring, and prescribing therapeutic strategies such as treatment with imatinib or other kinase inhibitors.

The invention provides a preparation method of a nose comforting tablet which is prepared from crude drugs including 100g of scutellaria baicalensis, 150g of Fructus Xanthii, 100g of violet magnolia, 75g of mint, 100g of radix angelicae, 25g of asarum, and 500g of dandelion through supercritical extraction and microwave extraction, so that the content of baicalein is greatly improved. The invention also provides the application of the nose comforting tablet in preparing a medicine for restraining proliferation of human melanoma cell, M14 cell.

Methods for melanoma treatment and prevention with selective nitric oxide synthase inhibitor compounds and related pharmaceutical compositions, alone or in conjunction with one or more other melanoma therapies.

The invention belongs to the field of biomedicines, relates to a novel medicinal application of a natural drug active ingredient juglone, and particularly relates to an application of juglone in preparation of a TRAIL sensitizer. An experiment proves that the killing effect of a TRAIL on two tumor cell lines, namely human melanoma cell lines MEWO and A2058 can be significantly strengthened through combined utilization of the juglone and the TRAIL, and separate application of the RAIL does not have an obvious effect on cell proliferation and apoptosis of the human melanoma cell lines MEWO and A2058.

The invention provides synthesis for a 4-(3-(3-(4-clocoumarol)-acylhydrazone)-5-phenyl-pyrazol) benzene sulfonamide derivate. The synthesis is characterized by being implemented according to the general formula (please see the formula in specification). The 4-(3-(3-(4-clocoumarol)-acylhydrazone)-5-phenyl-pyrazol) benzene sulfonamide derivate has the obvious inhibiting effect on culture of cervical cancer cells (Hela), human melanoma cells (F10) and hepatoma carcinoma cells (HepG2) and has cytotoxicity equivalent to or better than that of positive control drugs for human kidney epithelial cells (293T). Accordingly, the 4-(3-(3-(4-clocoumarol)-acylhydrazone)-5-phenyl-pyrazol) benzene sulfonamide derivate can be used for preparing anti-tumor drugs. The invention discloses a preparing method of the benzene sulfonamide derivate and anti-tumor biological activity.

The invention provides a substituted benzofuran derivative. A chemical structure of the derivative is as shown in general formula I. The invention further provides a preparation method of the formulaI, the preparation method is as shown in the following reaction formula described in the specification, wherein R and R' are defined the same as the specification. In-vitro proliferation inhibition experiment researches of human tumor cells show that the substituted benzofuran derivative has excellent inhibition effects on tumor cells such as human hepatoma cells HLF, human intestinal cancer cellsHCT116, human breast cancer cells MDA-MB-231, human prostate cancer cells DU145, human melanoma cells A375, human colon cancer cells Lovo, human kidney cancer cells 786-o, human chronic myeloid leukemia cells K562, human gastric cancer cells MGC-803, human pancreatic cancer cells PANC-1, can be used for preparing an anti-tumor drug, has low acute toxicity and good water solubility, and has good clinical application prospects. The preparation method provided by the invention is suitable for industrial production.

The invention provides a preparation method of an angelica sinensis and radix paeoniae alba liujun pill. The angelica sinensis and radix paeoniae alba liujun pill is prepared from 100g of angelica sinensis, 100g of fried white atractylodes rhizome, 100g of codonopsis pilosula, 100g of radix paeoniae alba, 100g of poria cocos, 50g of honey-fried licorice root, 50g of pericarpium citri reticulatae and 50g of ginger processed pinellia which are used as crude drugs by adopting supercritical extraction. Thus, the content is greatly improved, and the dose is reduced. The invention also provides application of the angelica sinensis and radix paeoniae alba liujun pill in preparation of a medicine for inhibiting cell proliferation of human melanoma cells (MV3).

The invention relates to the technical field of medicines, and in particular to an application of nano-microsphere containing orlistat in preparing antineoplastic drugs. The nano-microsphere consistsof the orlistat as well as any copolymer which is selected from a vitamin A methacrylate-2-methacryloyloxyethyl phosphorylcholine copolymer, a vitamin E methacrylate-2-methacryloyloxyethyl phosphorylcholine copolymer and a vitamin D methacrylate-2-methacryloyloxyethyl phosphorylcholine copolymer. Based upon in vitro test results, it is indicated that antineoplastic activity of the nano-microsphereprovided by the invention on human prostate cancer cells DU145, human melanoma cells A375 and human pancreatic cancer cell lines bxpc-3 is obviously higher than that caused by independent administration of the orlistat, and the antineoplastic activity is better than that of control nano-microsphere which is prepared by taking PMB30 as a carrier as well as nano-microsphere which contains the orlistat and polyethylene glycol-polycaprolactone.